Sam Brusco, Associate Editor09.27.22
Clinical monitoring firm Seer Medical has gained U.S. Food and Drug Administration (FDA) approval for its Seer Home to diagnose epilepsy through multi-day video-EEG-ECG monitoring.
The tech is an ambulatory electroencephalograph (EEG) system to be used at home for week-long studies. The wearable “Seer Sense” is worn on the shoulders with electrodes connected ot the skull and chest to record brain and heart (ECG) signals. The recordings are sent to a nearby monitoring hub that stores data from the wearable and records video footage synchronized to the EEG-ECG data.
The reviewing physician can use the recorded data for further context and information to help diagnosis of the neurological condition. Once the study is completed, the tech is returned to Seer and a qualified physician reviews and annotates the collected data to produce a report for the referring doctor.
“Seer has demonstrated the effectiveness of ambulant diagnostic monitoring in our home market of Australia. Now with this approval, we are delighted to be able to offer a new pathway to diagnosis for Americans with epilepsy—one that does not require a hospital stay and one that will give doctors the data they need to more accurately diagnose and monitor neurological disorders,” Dr. Dean Freestone, CEO and co-founder of Seer told the press.
There is a potential for the system to augment hospitals’ and healthcare providers’ monitoring capabilities.
“Seer's wireless EEG monitoring system and AI-enabled review platform have potential to help people with epilepsy or other episodic events access the care they need more quickly and with less disruption to their personal lives. This technology may be especially impactful in underserved areas with limited access to neurological healthcare resources,” said Dr. Ben Brinkmann, associate professor of neurology at Mayo Clinic.
The tech is an ambulatory electroencephalograph (EEG) system to be used at home for week-long studies. The wearable “Seer Sense” is worn on the shoulders with electrodes connected ot the skull and chest to record brain and heart (ECG) signals. The recordings are sent to a nearby monitoring hub that stores data from the wearable and records video footage synchronized to the EEG-ECG data.
The reviewing physician can use the recorded data for further context and information to help diagnosis of the neurological condition. Once the study is completed, the tech is returned to Seer and a qualified physician reviews and annotates the collected data to produce a report for the referring doctor.
“Seer has demonstrated the effectiveness of ambulant diagnostic monitoring in our home market of Australia. Now with this approval, we are delighted to be able to offer a new pathway to diagnosis for Americans with epilepsy—one that does not require a hospital stay and one that will give doctors the data they need to more accurately diagnose and monitor neurological disorders,” Dr. Dean Freestone, CEO and co-founder of Seer told the press.
There is a potential for the system to augment hospitals’ and healthcare providers’ monitoring capabilities.
“Seer's wireless EEG monitoring system and AI-enabled review platform have potential to help people with epilepsy or other episodic events access the care they need more quickly and with less disruption to their personal lives. This technology may be especially impactful in underserved areas with limited access to neurological healthcare resources,” said Dr. Ben Brinkmann, associate professor of neurology at Mayo Clinic.